# Apixaban

## ELIQUIS 5mg

| TAH Drug Code      | [OELI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OELI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), w/ >=1 risk factors [eg, prior stroke or transient ischaemic attack, age >=75 yr, HTN, DM, symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years, body weight =<60 kg, or serum creatinine >=1.5 mg/dL, then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | There is no clinical experience with apixaban in patients with creatinine clearance <15 mL/min or those undergoing dialysis; therefore, its use is not recommended. Active pathological bleeding. Severe hypersensitivity reactions to ELIQUIS (e.g., anaphylactic reactions). Liver disease associated with coagulopathy and a clinically significant risk of bleeding. Breastfeeding is not recommended during ELIQUIS treatment. ELIQUIS is not recommended for patients with severe hepatic impairment (Child-Pugh Class C).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Common: Contusion (1.4-2.2%), Bleeding gums (<0.1-1.4%), Hematoma (DVT, 1.3-1.5%), Menorrhagia (1.4%), Bleeding from nose (DVT and pulmonary embolism, 1.5-3.6%; DVT prophylaxis, 0.1-<1%), Hemoptysis (<0.1-1.2%) Serious: Gastrointestinal hemorrhage (Atrial fibrillation, 0.83%/year; DVT prophylaxis, 0.1-<1%; DVT and pulmonary embolism, 0.1-<1%), Hematochezia (0.1-<1%), Rectal hemorrhage (<0.1-1%), Upper gastrointestinal bleeding, Hemorrhage (Atrial fibrillation, 2.08%/year ; DVT prophylaxis, 2.88-4.83%), Hemorrhage (0.1-1.4%), Hemorrhage, Major (0.1-2.13%), Hemorrhage, Operative (DVT prophylaxis, 0.1-<1%), Alkaline phosphatase above reference range (DVT prophylaxis, 0.1-<1%), Liver function tests outside reference range (DVT prophylaxis, 0.1-<1%), Serum bilirubin above reference range (DVT prophylaxis, 0.1-<1%), Hypersensitivity reaction (atrial fibrillation, <1%), Hemorrhage of muscle (<0.1-<1%), Extradural intracranial hematoma, Intracranial hemorrhage (0.33-0.34% per year), Non-traumatic spinal subdural hematoma, Traumatic spinal subdural hematoma, Conjunctival hemorrhage (0.1-<1%), Retinal hemorrhage (0.1-<1%), Hematuria (DVT, 1.4-2.1% ; DVT prophylaxis, 0.1-<1%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/apixaban-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Eliquis 2.5mg

##### è‡¨æŽ¡

| TAH Drug Code      | [OELI2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OELI2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), w/ >=1 risk factors [eg, prior stroke or transient ischaemic attack, age >=75 yr, HTN, DM, symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years, body weight =<60 kg, or serum creatinine >=1.5 mg/dL, then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | There is no clinical experience with apixaban in patients with creatinine clearance <15 mL/min or those undergoing dialysis; therefore, its use is not recommended. Active pathological bleeding. Severe hypersensitivity reactions to ELIQUIS (e.g., anaphylactic reactions). Liver disease associated with coagulopathy and a clinically significant risk of bleeding. Breastfeeding is not recommended during ELIQUIS treatment. ELIQUIS is not recommended for patients with severe hepatic impairment (Child-Pugh Class C).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Common: Contusion (1.4-2.2%), Bleeding gums (<0.1-1.4%), Hematoma (DVT, 1.3-1.5%), Menorrhagia (1.4%), Bleeding from nose (DVT and pulmonary embolism, 1.5-3.6%; DVT prophylaxis, 0.1-<1%), Hemoptysis (<0.1-1.2%) Serious: Gastrointestinal hemorrhage (Atrial fibrillation, 0.83%/year; DVT prophylaxis, 0.1-<1%; DVT and pulmonary embolism, 0.1-<1%), Hematochezia (0.1-<1%), Rectal hemorrhage (<0.1-1%), Upper gastrointestinal bleeding, Hemorrhage (Atrial fibrillation, 2.08%/year ; DVT prophylaxis, 2.88-4.83%), Hemorrhage (0.1-1.4%), Hemorrhage, Major (0.1-2.13%), Hemorrhage, Operative (DVT prophylaxis, 0.1-<1%), Alkaline phosphatase above reference range (DVT prophylaxis, 0.1-<1%), Liver function tests outside reference range (DVT prophylaxis, 0.1-<1%), Serum bilirubin above reference range (DVT prophylaxis, 0.1-<1%), Hypersensitivity reaction (atrial fibrillation, <1%), Hemorrhage of muscle (<0.1-<1%), Extradural intracranial hematoma, Intracranial hemorrhage (0.33-0.34% per year), Non-traumatic spinal subdural hematoma, Traumatic spinal subdural hematoma, Conjunctival hemorrhage (0.1-<1%), Retinal hemorrhage (0.1-<1%), Hematuria (DVT, 1.4-2.1% ; DVT prophylaxis, 0.1-<1%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/apixaban-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

